ORIGINAL RESEARCH article
Sec. Cancer Genetics
Volume 8 - 2018 | https://doi.org/10.3389/fonc.2018.00323
BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
- 1Genotipificación y Cáncer Hereditario, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- 2Facultad de Medicina, Instituto de Investigaciones Biomédicas (INBIOMED), Universidad de Buenos Aires-CONICET, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- 3Hospital Universitario, Instituto de Genética, Universidad Nacional de Cuyo, Mendoza, Argentina
In Ashkenazi Jewish (AJ) high risk families 3 mutations [2 in BRCA1 (c. 68_69del and c.5266dup) and 1 in BRCA2 (c.5946del)] account for the majority of high risk breast and ovarian cancer cases in that ethnic group. Few studies with limited number of genotyped individuals have expanded the spectrum of mutations in both BRCA genes beyond the 3 mutation panel. In this study, 279 high risk individual AJ were counseled at CEMIC (Centro de Educación Médica e Investigaciones Clínicas), and were genotyped first for the 3 recurrent mutation panel followed by Next Generation Sequencing (NGS) of BRCA1 BRCA2 in 76 individuals who tested negative for the first genotyping step. Of 279 probands (259 women), 55 (50 women) harbored one of the 3 mutations (19.7%); Of 76 fully sequenced cases (73 women), 6 (5 women) (7.9%) carried a pathogenic mutation: in BRCA1, c.2728C>T - p.(Gln910*); c.5407-?_(*1_?)del and c.5445G>A - p.(Trp1815*); in BRCA2, c.5351dup - p.(Asn1784Lysfs*3); c.7308del - p.(Asn2436Lysfs*33) and c.9026_9030del - p.(Tyr3009Serfs*7). Of 61 mutation carriers the distribution was as follows: 11 cancer free at the time of genotyping, 34 female breast cancer cases with age range 28–72 years (41.6 ± 9.3), 3 male breast cancer cases with age range 59–75 years (65 ± 7.3), 6 breast and ovarian cancer cases with age range 35–60 years (breast 40.4 ± 5.2; ovary 47.8 ± 7.2) and 7 ovarian cancer cases with age range 41–77 years (60.6 ± 13.3). This information proved highly useful for counseling, treatment, and prevention for the patient and the family. In conclusion comprehensive BRCA1/2 testing in AJ high risk breast ovarian cancer cases adds valuable clinically relevant information in a subset of cases estimated up to 7% and is therefore recommended.
Inherited pathogenic mutations in BRCA1 (OMIM*113705) or BRCA2 (OMIM*600185) substantially increase lifetime risk for breast, ovarian and to a lesser extent other cancer types defining individuals who carry BRCA1 or BRCA2 cancer predisposing mutations is valuable for both cancer cases and unaffected family members: targeted treatment in the form of PARP inhibitors is available for mutation carrying patients (1, 2), and early detection schemes and risk-reducing strategies are offered to asymptomatic mutation carriers (3, 4).
Near 300 BRCA1 and BRCA2 pathogenic mutations in the Argentine population have been reported by our group (5, 6) routinely deposited in Leiden Open Variation Database 3.0 (7) and Leiden Open Variation Database–Chapter for Argentina (8), most previously described in other world populations with ~10% of novel pathogenic variants.
The estimated frequency of pathogenic germline mutations in BRCA1 and BRCA2 genes in the general population in several outbred populations vary between 1:300 and 1:800, respectively (4). However, in inbred populations, with AJ as one of the most frequently studied examples, the spectrum of BRCA mutations is limited with higher rates in the general population. In this ethnic group 1/40 individuals is a carrier one of 3 recurrent mutations in BRCA1 [185delAG: c.68_69del (rs386833395) and 5382insC: c.5266dup (rs80357906)], and BRCA2 [6174delT: c.5946del (rs80359550)]. Such high rates in the general population and consecutive breast and ovarian cancer cases enabled effective use of cancer genetics services for AJ women (9).
For high risk AJ individuals not carrying one of these 3 founder alleles, the probability for other pathogenic mutations in BRCA1 or BRCA2 has rarely been reported (10–13). In the current study we report on an extended analysis of BRCA1/2 by comprehensive next generation sequencing and analysis of point mutations and large rearrangements in Ashkenazi patients with personal and/or family history of cancer qualifying for the panel analysis and testing normal for the 3 founder mutations.
Materials and Methods
The study focused on Ashkenazi Jewish individuals recruited from those referred for counseling and genotyping at CEMIC (Centro de Educación Médica e Investigaciones Clínicas) between 2009 and 2017. Eligibility criteria for patient selection are based on the NCCN guidelines [National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 1.2018) https://www.nccn.org/ Accessed March 30, 2018]. For individuals of AJ origin, with no known familial mutation, were first tested for the 3 AJ specific mutations (see below genotyping methodology). Then, for high risk individuals of AJ who tested negative for the three mutations BRCA comprehensive BRCA genetic testing was carried out (see below genotyping platform). Study eligibility after genetic counseling required signing an informed consent as part of the routine procedures for genetic analysis (including Ethics Committee approval) at CEMIC, which also complies with the Traditional Pretest Counseling for Susceptibility Testing (purpose of testing) described in the American Society of Clinical Oncology Policy Statement Update (14).
BRCA1/2 Testing Platforms
Genomic DNA of the 279 blood samples was isolated by MagNA Pure® LC instrument with total DNA isolation kit I (Roche Diagnostics). All samples were analyzed by Sanger sequencing of PCR amplified fragments for the 3 founder Ashkenazi mutations c.68_69del and c.5266dup in BRCA1 and c.5946del in BRCA2.
Analysis of comprehensive BRCA1/2 sequencing and large rearrangements by Multiple Ligation-dependent Probe Amplification assay (MLPA) for eligible individuals was performed by Next Generation Sequencing (NGS) by using the Ion AmpliSeqBRCA1/2 community panel, as it allows to amplify the entire coding sequences of BRCA1 and BRCA2, including 20–50 bases of adjacent intronic sequence of each exon. The assay is designed to ensure at least 200X total coverage/base. Sequencing of the amplified regions was performed with the next generation platform Personal Genome Machine® System, as previously described (6). Rare coding sequences with low coverage were analyzed by Sanger sequencing to ensure higher coverage rates. The raw signal data and the sequence reads were processed with Ion Torrent Suite software (Thermo Fisher Scientific) on a Torrent server. After data analysis, single nucleotide variants, insertions, deletions, and splice site alterations were registered, and all variants detected were reported. Sanger sequencing was used to confirm all clinically relevant variants detected (class 3, 4, and 5). Clinical significance was determined according to the reference databases: ClinVar (15), LOVD3.0 (7), and UMD (16) as of March 2018.
For missense mutations not reported or reported with uncertain clinical significance (VUS), in silico programs were used to predict the change in protein function using software Align-GVGD (http://agvgd.iarc.fr/), SIFT (http://sift.bii.a-star.edu.sg), and Mutations Taster (http://www.mutationtaster.org/).
Large rearrangements were measured by MLPA using SALSA MLPA Probemix P002 and P045 provided by MRC-Holland, and Coffalyser.net software was used for data analysis; we confirm the positive results with P087 and P077 for BRCA1 and BRCA2, respectively.
Overall, we include 279 patients (Figure 1) recruited among 2009–2017 as depicted in Table 1. Age range at counseling and genotyping was 20–87 years; 181 (174 females) had cancer diagnoses (mean age 48.3 ± 11.2 years) and 98 were healthy, cancer free high risk individuals (mean age at genotyping 47.7 ± 11.8). Of cancer cases the distribution was as follows: of 174 cancer affected women, breast, 145 (age range 28–74 years, mean 47.0 ± 9.6), breast and ovarian 7 (age range breast 35–64 years, mean 44.3 ± 9.8; age range ovary 41–64 years, mean 49.2 ± 8.9), ovarian 19 (age range 18–78 years, mean 52.5 ± 16.6) and one each with pancreas (68 years), endometrium (58 years) and melanoma (26 years). For the 7 cancer affected men, 6 had breast cancer (age range 59–75 years; mean 65.5 ± 5.7) and 1 with prostate cancer (61 years).
Figure 1. Patients of Ashkenazi origin with personal and/or family history (279 probands) were tested for the panel AJ founder mutations; among affected patients 24.3% were detected with a mutation while this rate was 11.2% in the non-affected individuals. Sixty three patients without AJ mutation were subjected to the comprehensive BRCA1/2 analysis and 6 were diagnosed with a pathogenic mutation (9.5% from the analyzed probands). On the other hand, 98 were healthy individuals with family history of cancers related to BRCA1/2 and, among them. The non-Ashkenazi mutations were detected always in affected patients.
The 279 selected patients were first analyzed through the AJ founder mutation and, among those who tested normal, 76 patients were analyzed by the BRCA1/2 comprehensive study; among the 6 patients with a non AJ mutation detected all but 2 were of full AJ origin, one was mixed Ashkenazi non Ashkenazi and the other mixed Ashkenazi and non-Jewish. The ages ranged from 20 to 87 years old; 181 of them were affected with a mean age of 48.3 ± 11.2 and 98 of them were healthy with a mean age of 47.7 ± 11.8. Table 1 summarizes the age range and mean age ± SD for subjects with a mutation detected separated by diagnosis and gender. As eligible patients we included men or women selected by their AJ ethnicity, with two exceptions (Figure 2): proband [B: BRCA1 c.5407-?_(*1_?)del] was half Sephardi, and proband [D: BRCA2: c.5351dup - p.(Asn1784Lysfs*3)] was half non-Jewish, although this side was not the side associated with inheritance of the syndrome.
Figure 2. Pedigrees of the families carrying mutations in BRCA1/2 other than the Ashkenazi founder mutations. Circles: women; squares: men; half blackened symbols: individuals affected with cancer; white symbols: unaffected individuals; TN: triple negative breast cancer; slash diagonal line: deceased. The cancer and age at diagnosis are indicated below each individual when available. An arrow indicates the proband. (A) BRCA1 c.2728C>T - p.(Gln910*); (B) BRCA1 c.5407-?_(*1_?)del; (C) BRCA1: c.5445G>A-p.(Trp1815*); (D) BRCA2: c.5351dup - p.(Asn1784Lysfs*3); (E) BRCA2 c.7308del - p.(Asn2436Lysfs*33); (F) BRCA2 c.9026_9030del - p.(Tyr3009Serfs*7).
Overall, 61/279 genotyped cases (21.8%) harbored a BRCA1 mutation (n = 44) or a BRCA2 mutation (n = 17). Of these mutations all but 3 in BRCA1 and 3 in BRCA2 were one of the predominant AJ mutations in both genes.
Table 1 summarizes age at genotyping and/or cancer diagnosis and type and gender of all mutation carriers and the specific unique non founder mutations.
Figure 1 summarizes the genotype analysis of 279 individuals with the DNA sequenced for the panel of the 3 founder Ashkenazi mutations and full sequence by NGS technique and MLPA.
Table 1 lists the patients with a mutation detected, to be remarked women with diagnosis of breast cancer were the youngest (range starts at 28 years), mean age non-statistically different from women with diagnosis of both, breast and ovary cancer.
Figure 2 depicts the pedigrees for the six families with a non AJ founder mutation. Of the 6 mutations found, BRCA2 c.7308del - p.(Asn2436Lysfs*33) has not been previously reported and is therefore novel while the other 5 have been reported in non-Jewish populations.
Regarding the families with a non-Ashkenazi mutation, the particular details of the family history of cancers related to BRCA was strong for the 6 probands, as shown in the pedigrees drawn in Figure 2. The description of the mutations are in Table 4, as follows: BRCA1: c.2728C>T - p.(Gln910*), rs397509004, c.5407-?_(*1_?)del, c.5445G>A - p.(Trp1815*), rs397509284 and BRCA2: c.5351dup - p.(Asn1784Lysfs*3), rs80359508, c.7308del - p.(Asn2436Lysfs*33), c.9026_9030del - p.(Tyr3009Serfs*7), rs80359741.
Table 4. Families with a non-AJ founder mutation in BRCA1/2 from pedigrees drawn in Figure 2.
The likelihood that AJ high risk individuals who do not carry any of the predominant AJ mutations in BRCA1 and BRCA2 would harbor a unique BRCA1 or BRCA2 mutation in the present study was 7.9%. As the family D was self-reported as half-non AJ, the resulting prevalence for BRCA1/2 non AJ mutation excluding this family results to be 5 out of 76 cases (6.6%). This rate is line with previous studies, although there are only a few that have reported such a focused analysis (10–13). In those previous studies the rates were 4-5% of fully genotyped AJ cases. The rationale behind our two step sample analysis approach lies in the fact that non-routine tests in the Argentinian health care system requires approval by a specialized committee that tends to not approve oncogenetic testing for unaffected individuals despite having a significant family history of cancer.
A rather difficult task is to express the results of this study, as not all the patients without an Ashkenazi mutation were analyzed by NGS and MLPA. As a consequence, the percentages of mutations cannot be straightforwardly interpreted, which may constitute a limitation for expressing the current findings. However, our results still remain valid, as even if all samples normal for the Ashkenazi panel had been tested for the comprehensive BRCA1/2 study and no other mutation would had been detected, the percentage obtained would still have been 3.3% (6 out of 181 affected patients).
The population targeted in this study was selected on the basis of clinically having features of inherited cancer syndrome. Overall, non AJ mutations were detected in 6.8% of female cancer cases; 4.1% in female breast cancer cases and 2.7% in ovarian cancer (alone or with breast cancer). These rates are higher than those previously reported for Ashkenazi population, likely due to different criteria used for patient selection (10, 11). The highest mutation rates were found in cases of ovarian cancer including breast cancer diagnosed in the same patient, 50%, with similar rates to what was previously published by our group in a description of 940 patients (6).
Worth highlighting, 11 out of these 13 mutations were among the Ashkenazi panel and two detected by full analysis. The two probands found to carry a mutation in BRCA1/2 support the application of precision medicine: patients benefit from being considered for poly–(adenosine diphosphate–ribose) polymerase (PARP) inhibitor therapy (1, 2), while their families still qualify for prevention measures as the first goal in these genetic studies.
Family history of cancer in first degree relatives as a major selection criterion for selecting cases to be genotyped carries an inherent limitation, as gender specific cancer (e.g., ovarian cancer) cannot be used in cases where the mutation arises on the paternal side yet, the value of incorporating second or third degree relatives on either parental side has its own merits. Moreover there are cases where the family history is distinct or the paternal from the maternal sides and both should be taken into account and guide the genetic testing platform. A case that exemplifies this point is the patient who co-harbored the MSH2 c.1906G>C - p.(Ala636Pro) (17) and BRCA1 c.68_69del - p.(Glu23Valfs*17). These findings are of the utmost importance, as surveillance of the unaffected proband will focus on both Lynch and hereditary breast-ovary cancer syndromes, while genetic counseling will be crucial for both paternal and maternal relatives.
The results of this study support the guidelines recommending genetic testing for the recurrent BRCA mutations in all AJ breast and ovarian cancer patients (NCCN Clinical Practice in Oncology, Version 1.2018). In addition, the value, albeit limited to <8% more mutations, of an extended comprehensive BRCA genotyping for high risk Ashkenazim who are negative for the 3 predominant mutations needs to be offered and discussed with the patients at genetic counseling, regardless of the cost. This is particularly important as having a BRCA mutation has therapeutic implications especially in ovarian cancer cases, who can benefit from PARP inhibitor treatment.
AS, FC, and EP discussed the conception of the work and take responsibility for data integrity and the accuracy of data analysis. FJ, NL, AM, and DF collected and organized patient samples. PM, FJ, and DF analyzed the literature and evaluated statistics. All authors critically revised the manuscript for important intellectual content.
Partially funded by grant of Instituto Nacional del Cáncer, Ministerio de Salud de la República Argentina, Res. 0515.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors are grateful to all the patients who participated in this study. We also want to thank the CEMIC team for the careful selection and dedication to patient attention, specially to: Bruno Luisina, Canosa Isabel, De La Vega Maximo, Diaz Canton Enrique, Garrido Rosa, Gomez Abuin Gonzalo, Greco Martin, Kalfayan Pablo, Korbenfeld Ernesto, Lippold Santiago, Moya Graciela, Nuñez Lina, Perazzo Florencia, Recondo Gonzalo, Santillan Francisco, Vuotto Carlos.
1. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376:245–51. doi: 10.1016/S0140-6736(10)60893-8
2. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Eng J Med. (2012) 366:1382–92. doi: 10.1056/NEJMoa1105535
3. Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. (2015) 21:211–20. doi: 10.1158/1078-0432.CCR-14-1816
4. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annal Oncol. (2016) 27(Suppl. 5):v103–v10. doi: 10.1093/annonc/mdw327
5. Solano AR, Aceto GM, Delettieres D, Veschi S, Neuman MI, Alonso E, et al. BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. SpringerPlus (2012) 1:20. doi: 10.1186/2193-1801-1-20
6. Solano AR, Cardoso FC, Romano V, Perazzo F, Bas C, Recondo G, et al. Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice. Oncotarget (2017) 8:60487–95. doi: 10.18632/oncotarget.10814
7. Leiden Open Variation Database 3.0 Available online at: http://www.lovd.nl/3.0/home [Internet] (Accessed March 30, 2018).
8. Leiden Open Variation Database (Chapter for Argentina) Available online at: http://ar.lovd.org [Internet].
9. Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, et al. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. Genet Med. (2017) 19:754–62. doi: 10.1038/gim.2016.182
10. Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat. (2015) 149:223–7. doi: 10.1007/s10549-014-3218-x
11. Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncol. (2017) 3:1647–53. doi: 10.1001/jamaoncol.2017.1996
12. Ganguly T, Dhulipala R, Godmilow L, Ganguly A. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Hum Genet. (1998) 102:549–56.
13. Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, et al. Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat. (2011) 127:489–95. doi: 10.1007/s10549-010-1217-0
14. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. (2015) 33:3660–7. doi: 10.1200/JCO.2015.63.0996
15. ClinVar Available online at: http://www.ncbi.nlm.nih.gov/clinvar/ [Internet] (Accessed March 30, 2018).
16. Universal Mutation Database (UMD). Available online at: http://www.umd.be/ [Internet] (Accessed March 30, 2018).
17. Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, et al. The founder mutation MSH2*1906G–>C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet. (2002) 71:1395–412. doi: 10.1086/345075
19. Campos B, Diez O, Odefrey F, Domenech M, Moncoutier V, Martinez-Ferrandis JI, et al. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain. Hum Mutat. (2003) 21:452. doi: 10.1002/humu.9133
Keywords: non-founder Ashkenazi BRCA1/2 mutations, Ashkenazi Jewish, hereditary breast and ovary cancer, BRCA1, BRCA2
Citation: Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC and Podesta EJ (2018) BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina. Front. Oncol. 8:323. doi: 10.3389/fonc.2018.00323
Received: 15 May 2018; Accepted: 30 July 2018;
Published: 21 August 2018.
Edited by:Paolo Peterlongo, IFOM–The FIRC Institute of Molecular Oncology, Italy
Reviewed by:Fabienne Lesueur, INSERM U900 Cancer Et Génome Bioinformatique, Biostatistiques Et Épidémiologie, France
Eitan Friedman, Sheba Medical Center, Israel
Copyright © 2018 Solano, Liria, Jalil, Faggionato, Mele, Mampel, Cardoso and Podesta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Angela R. Solano, email@example.com